Targeting CD19 in Diffuse Large B-Cell Lymphoma: Treatment Updates

Video

A key opinion leader provides an overview of emerging data for a promising CD-19 targeted therapy and discusses how it has impacted the treatment paradigm.

Recent Videos
1 KOL is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
Hope S. Rugo, MD, FASCO, is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL

Zilovertamab Vedotin/R-CHP Elicits High Complete Response Rate in DLBCL

Silas Inman
Published: December 8th 2024 | Updated: December 8th 2024
Article

The addition of zilovertamab vedotin to R-CHP (cyclophosphamide, doxorubicin, prednisone, rituximab) resulted in a 100% complete response rate in patients with previously untreated DLBCL.

Read More

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

The Road to Improving Diffuse Large B-Cell Lymphoma Treatment

Nichole Tucker
June 15th 2022
Podcast

In season 3, episode 5 of Targeted Talks, Thomas Habermann, MD, discusses the upcoming advances in the treatment of diffuse large B-cell lymphoma.

Listen

FDA Accepts sBLA for Glofitamab Plus Chemo in DLBCL

FDA Accepts sBLA for Glofitamab Plus Chemo in DLBCL

Jordyn Sava
December 5th 2024
Article

The FDA has accepted an sBLA for glofitamab plus gemcitabine and oxaliplatin in relapsed/refractory diffuse large B-cell lymphoma.

Read More

Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL

Lunning Evaluates CAR T-Cell Therapy for ASCT-Eligible and Ineligible DLBCL

Targeted Oncology Staff
September 22nd 2024
Article

During a Case-Based Roundtable® event, Matthew A. Lunning, DO, discussed the updated trial data for 2 chimeric antigen receptor T-cell therapies in patients with diffuse large B-cell lymphoma.

Read More

Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma

Superior Outcomes With Brentuximab Vedotin Triplet in Diffuse Large B-Cell Lymphoma

Kristi Rosa
September 11th 2024
Article

The addition of brentuximab vedotin to lenalidomide and rituximab significantly improved survival and response vs lenalidomide/rituximab alone in patients with relapsed/refractory DLBCL.

Read More

Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL

Saeed Discusses Long-Term Outcomes and Real-World Data for Tafasitamab/ Lenalidomide in R/R DLBCL

Targeted Oncology Staff
August 15th 2024
Article

During an in-person Community Case Forum event, Hayder Saeed, MD, discussed the RE-MIND2 matched cohort data and real-world data on the combination of tafasitamab and lenalidomide in patients with diffuse large B-cell lymphoma.

Read More